Summary by Moomoo AI
A regulatory filing with the United States Securities and Exchange Commission (SEC) on January 2, 2024, revealed that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz collectively reported a 4.99% stake in Avenue Therapeutics, Inc. The filing, an amendment to Schedule 13G, indicates shared voting and dispositive power over 661,056 shares of the company's common stock. Sabby Management, LLC, as the investment manager of Sabby Volatility Warrant Master Fund, Ltd., and Hal Mintz, in his capacity as manager of Sabby Management, LLC, do not directly own any shares but have an indirect interest in the same number of shares. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avenue Therapeutics, Inc. The principal executive offices of Avenue Therapeutics are located at 1140 Avenue of the Americas, Floor 9, New York, NY 10036.